

100500913

DT04 Rec'd PCT/PTO 08 JUL 2004

## **APPENDIX C**

**(Statements Under 37 C.F.R. §§ 1.821 and 1.825)**

**(Serial No. not yet assigned)**

10/500913

DT04 Rec'd PCT/P10 08 JUL 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Application of:**

Van Gilst et al.

**Serial No.:** To be assigned

**Filed:** July 8, 2004

**For:** USE OF ERYTHROPOIETIN FOR  
THE PREVENTIVE OR CURATIVE  
TREATMENT OF CARDIAC FAILURE

**Examiner:** To be assigned

**Group Art Unit:** To be assigned

**Attorney Docket No.:** 2578-6485US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV326921367US

Date of Deposit with USPS: July 8, 2004

Person making Deposit: Christopher Haughton

STATEMENT UNDER 37 C.F.R. §§ 1.821 THROUGH 1.825

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

I, G. Scott Dorland, Ph.D., an attorney registered to practice before the United States Patent & Trademark Office and attorney of record for this application, state that:

1. The enclosed paper copy of the SEQUENCE LISTING and the enclosed copy of the SEQUENCE LISTING in computer readable form (CRF) have been prepared to comply with the requirements of 37 C.F.R. §§ 1.821 through 1.825.

10/500913

DT04 Rec'd PCT/PTO 08 JUL 2004

Attorney Docket No.: 2578-6485US

2. The enclosed CRF copy of the SEQUENCE LISTING is believed to be identical to the paper copy of the SEQUENCE LISTING.

Respectfully submitted,



G. Scott Dorland, Ph.D.  
Registration No. 51,622  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: July 8, 2004

GSD/bv

Document in ProLaw